Global Hypertriglyceridemia Therapeutics Market to Generate Revenue of US$ 12,863.1 Million by end of 2027, Says Coherent Market Insights

SEATTLE--()--According to Coherent Market Insights, the global hypertriglyceridemia therapeutics market is estimated to be valued at US$ 9,716.6 million in 2020 and is projected to exhibit a CAGR of 4.09% during the forecast period (2020-2027).

Key Trends and Analysis:

The global hypertriglyceridemia therapeutics market is expected to witness considerable growth owing to approvals of novel drugs for the treatment of hypertrigleridemia and related cardiovascular diseases. For instance, in January 2020, Amarin Corporations’ VASCEPA was approved in Canada to minimize the risk of cardiovascular events. VASCEPA capsules are FDA approved for use as adjunct therapy to diet to lessen triglyceride levels in adult patients with severe hypertriglyceridemia.

Key players in the industry are involved in research and development, and launch of novel products which is expected to support growth of the market growth. For instance, in July 2019, Sun Pharma announced the launch of ‘Ezallor Sprinkle’ (Rosuvastatin) in the U.S. Ezallor Sprinkle capsules are specially developed for the people who have difficulty in swallowing. These capsules are indicated as an adjunct to the diet for the treatment of hypertriglyceridemia in adult patients. It is also indicated as an adjunct to diet for the treatment of adult patients with lipid-lowering and type III hyperlipoproteinemi.

Request for Sample PDF copy @ https://www.coherentmarketinsights.com/insight/request-sample/4020

Key Market Takeaways:

The global hypertriglyceridemia therapeutics market is expected to register a CAGR of 4.09% during the forecast period (2020-2027) owing to the increasing focus of pharmaceutical companies on developing novel drugs for hypertriglyceridemia. For instance, currently, a number of promising triglyceride-lowering therapies are at various stages of clinical development.

The North America hypertriglyceridemia therapeutics market is estimated to be the most lucrative during the period of forecast owing to product launches and presence of major players in the region. In July 2016, ‘Rosuvastatin Calcium Tablets’ were launched by Mylan in the U.S., which is the generic version of AstraZeneca’s Crestor Tablets for the treatment of hypertriglyceridemia.

Key players operating in the global hypertriglyceridemia therapeutics market are

Accord Healthcare, Sanofi, Aurobindo Pharma, GlaxoSmithKline Plc, Amneal pharmaceutical LLC, Biocon, Novo Nordisk A/S, Zydus Pharmaceuticals Inc., Tonghua Dongbao Pharmaceutical Co., Ltd., Glenmark, Oramed Pharmaceuticals, Inc, Julphar, Merck & Co., Inc., Pfizer, Inc., Wockhardt, Bristol-Myers Squibb Company, Eli Lilly and Company, Adocia, Hikma Pharmaceutical PLC, AbbVie Inc., and Lupin Ltd.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4020

Market Segmentation:

  • Global Hypertriglyceridemia Market, By Type:
    • Primary
    • Secondary
  • Global Hypertriglyceridemia Market, By Drug Class:
    • Statins
    • Fibrates
    • Niacin
    • Omega-3 Fatty Acids
    • HMG-CoA Reductase inhibitors
  • Global Hypertriglyceridemia Market, By Distribution Channel:
    • Online Pharmacy
    • Retail Pharmacy
    • Hospital Pharmacy
  • Global Hypertriglyceridemia Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
  • Asia Pacific
    • By Country:
      • Australia
      • India
      • China
      • Japan
      • ASEAN
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East
    • By Country:
      • GCC
      • Israel
      • Rest of Middle East

Related Market Intelligence Report:

Chordoma Disease Therapeutics Market, by Drug Class (Antimetabolites, Anthracycline, VEGFR Inhibitors, EGFR Inhibitor, and Others), by Treatment Type (Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), by End User (Hospitals, Clinics, Oncology Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more: https://www.coherentmarketinsights.com/market-insight/chordoma-disease-therapeutics-market-3979

Diabetes Devices and Drugs (Diagnosis, Monitoring, and Therapeutics) Market, By Category (Diagnosis and Monitoring (Blood Glucose Monitoring Devices, Other Testing Devices, Software Programs for Diabetes Monitoring, Artificial Pancreas), Therapeutics (Insulin, Insulin Delivery, Oral Hypoglycemic Agents, Cell Therapies)), By Disease Type (Type 2 Diabetes, Type 1 Diabetes), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more: https://www.coherentmarketinsights.com/market-insight/diabetes-devices-and-drugs-market-3857

Contacts

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter

Release Summary

The North America hypertriglyceridemia therapeutics market is estimated to be the most lucrative during the period of forecast.

Contacts

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter